Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Equillium

Why Is Equillium Stock Soaring Monday?

Equillium Inc. (NASDAQ:EQ) stock traded higher Monday after the company announced up to $50 million in financing through a securities purchase agreement with investors to advance EQ504.

3 Biotech Stocks Under $20 Worth Watching in June

3 Biotech Stocks Under $20 Worth Watching in June

The biotech industry’s long-term expansion is fueled by increasing medical needs globally, favorable government support, and technological advances. Given the industry’s rosy outlook, quality biotech stocks Equillium (EQ), SIGA Technologies (SIGA), and Shionogi & Co. (SGIOY) trading under $20 could be worth watching in June. Keep reading….

Eyeing Growth? Check Out These 3 Biotech Stock Buys

Eyeing Growth? Check Out These 3 Biotech Stock Buys

Robust government support coupled with rapid tech advancements is bolstering the biotech sector. Hence, investors eyeing growth might buy fundamentally solid biotech stocks Theratechnologies (THTX), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), with massive growth potential. Read on.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Smart Biotech Picks for Your 2024 Portfolio

The biotech industry is expanding as a result of consistent technological advancements and rising investments. So, it could be wise to buy quality biotech stocks Equillium (EQ), Shionogi (SGIOY), and Theratechnologies (THTX) in 2024. Read on.

3 Revolutionary Biotech Stocks Worth Investing In

The biotech industry's upward momentum is underpinned by the growth of personalized medicine, orphan drugs, innovative biotech tools, and robust government backing. Hence, revolutionary biotech stocks Equillium (EQ), Protalix BioTherapeutics (PLX), and Incyte Corporation (INCY) could make ideal additions to your portfolio at present. Read more….

Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock

Olumiant (baricitinib), a Janus kinase (JAK) inhibitor, was developed by Incyte Corp (NASDAQ:INCY) and launched in collaboration with Eli Lilly And Co (NYSE:LLY), received FDA approval for hair loss disorder known as alopecia areata (AA). Olumiant was first approved for the treatment of rheumatoid arthritis (RA) in 2018. The above nod is expected to…

Equillium's Itolizumab Shows Durable Clinical Response In GvHD Patients

Equillium Inc (NASDAQ: EQ) announced two oral presentations on itolizumab at the Annual Meeting of the European Society for Blood and Marrow Transplantation.

inkl

Read news from The Economist, FT, and more,
with one subscription

Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition

Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition

Equillium Inc (NASDAQ: EQ), with only one asset in its pipeline, is expanding its drug development efforts via the

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Eli Lilly And Co

Incyte Corporation

BioMarin Pharmaceutical Inc

Shionogi Co Ltd

SIGA Technologies Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Rheumatoid Arthritis

Places

314,257 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play